LH : Summary for Laboratory Corporation of Ameri - Yahoo Finance

U.S. Markets open in 5 hrs.

Laboratory Corporation of America Holdings (LH)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
140.27+1.25 (+0.90%)
At close: 4:02PM EST
People also watch
DGXHUMMCKPDCOWAT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close139.02
Open139.54
Bid0.00 x
Ask0.00 x
Day's Range138.94 - 140.80
52 Week Range108.95 - 141.32
Volume1,079,792
Avg. Volume798,132
Market Cap14.45B
Beta1.14
PE Ratio (TTM)19.98
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals11 hours ago

    LabCorp to buy 1,600-employee Washington firm

    Burlington-based Laboratory Corporation of America Holdings said late Thursday that it has entered into an agreement to purchase Spokane, Wash.-based medical testing company Pathology Associates Medical Laboratories LLC from Providence Health & Services and Catholic Health Initiatives. Terms of the deal with PAML were not disclosed.

  • Business Wire12 hours ago

    LabCorp to Acquire Pathology Associates Medical Laboratories from Providence Health & Services and Catholic Health Initiatives

    Laboratory Corporation of America® Holdings , Providence Health & Services and Catholic Health Initiatives , today announced that they have entered into a definitive agreement for LabCorp to acquire all of the ownership interest in Pathology Associates Medical Laboratories, LLC, , one of the nation’s premier medical reference laboratories and a healthcare solutions company jointly owned by Providence ...

  • American City Business Journals18 hours ago

    Medford's Seventh Sense wins narrow FDA approval for blood-collection device

    Medford biotech Seventh Sense Biosystems said Thursday that the FDA has approved its push-button blood-collection device for use by healthcare professionals to monitor blood sugar. The move by the FDA allows Seventh Sense to market the device, called TAP, for monitoring blood sugar levels in diabetic and pre-diabetic patients. The privately-held, 25-employee company has billed TAP as the world's first push-button blood collection device.